Skip to main content
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG — Investor Relations & Filings

Ticker · CRSP ISIN · CH0334081137 LEI · 506700O6IRRIQLT3W370 US Manufacturing
Open in API
Filings indexed 823 across all filing types
Latest filing 2017-04-21 Director's Dealing
Country CH Switzerland
Listing US CRSP

About CRISPR Therapeutics AG

https://crisprtx.com/

CRISPR Therapeutics AG is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company leverages this technology to make precise, directed changes to genomic DNA. As a pioneer in the field, CRISPR Therapeutics has established a diverse portfolio of therapeutic programs across several disease areas, including hemoglobinopathies (such as sickle cell disease and beta-thalassemia), immuno-oncology, regenerative medicine, and cardiovascular disease. The company was one of the first to advance a CRISPR-based therapy into clinical trials and receive regulatory approval, aiming to create potentially curative treatments for patients.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-04-21 English
FORM 4 SUBMISSION
Director's Dealing
2017-04-21 English
FORM 4 SUBMISSION
Director's Dealing
2017-04-21 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the Annual General Meeting (AGM) of shareholders. It includes detailed proposals for shareholder votes such as approval of the annual report, election of board members, compensation approvals, and other governance matters. The document is not the annual report itself but proxy materials for the AGM. The presence of voting proposals, instructions for voting, and references to the AGM date confirm this is proxy solicitation material. Therefore, the filing type corresponds to Proxy Solicitation & Information Statement (PSI).
2017-04-18 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes a press release about an appeal of a patent board decision, attached as an exhibit. There are no financial statements, detailed financial data, or management discussion present. The document is relatively short (3028 characters) and primarily serves as a regulatory announcement of an event rather than a detailed report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-04-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.